Cargando…

A dual role of miR-22 modulated by RelA/p65 in resensitizing fulvestrant-resistant breast cancer cells to fulvestrant by targeting FOXP1 and HDAC4 and constitutive acetylation of p53 at Lys382

Antiestrogen resistance is a major challenge encountered during the treatment of estrogen receptor alpha positive (ERα(+)) breast cancer. A better understanding of signaling pathways and downstream transcription factors and their targets may identify key molecules that can overcome antiestrogen resi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Bo, Li, Dongping, Filkowski, Jody, Rodriguez-Juarez, Rocio, Storozynsky, Quinn, Malach, Megan, Carpenter, Emily, Kovalchuk, Olga
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064715/ https://www.ncbi.nlm.nih.gov/pubmed/30057418 http://dx.doi.org/10.1038/s41389-018-0063-5

Ejemplares similares

Retrospective Evaluation of Fulvestrant Efficacy and Clinical Results in Patients Using Fulvestrant
por: Kut, Engin, et al.
Publicado: (2023)

Fulvestrant: pharmacokinetics and pharmacology
por: Robertson, J F R, et al.
Publicado: (2004)

A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells
por: Wang, Bo, et al.
Publicado: (2018)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

Fulvestrant-induced toxic epidermal necrolysis
por: Morales-Conde, Macarena, et al.
Publicado: (2019)

A Review of Fulvestrant in Breast Cancer
por: Nathan, Mark R., et al.
Publicado: (2017)

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
por: Schmid, Peter, et al.
Publicado: (2019)

Revisiting Fulvestrant Dosing in Uncertain Economic Times
por: Patel, Amol, et al.
Publicado: (2021)

High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo
por: Lehmann, Annika, et al.
Publicado: (2009)

The acetylation of RelA in Lys310 dictates the NF-κB-dependent response in post-ischemic injury
por: Lanzillotta, A, et al.
Publicado: (2010)

The acetylation of RelA in Lys310 dictates the NF-κB-dependent response in post-ischemic injury
Publicado: (2010)

Fulvestrant and the sequential endocrine cascade for advanced breast cancer
por: Johnston, S
Publicado: (2004)

Oestradiol measurement during fulvestrant treatment for breast cancer
por: Owen, Laura J., et al.
Publicado: (2019)

Abemaciclib/fulvestrant: Leucopenia and Covid-19: case report
Publicado: (2020)

Fulvestrant-Big Mac Index: Defining Inequality in Oncology
por: O'Reilly, David, et al.
Publicado: (2021)

Subinhibitory Concentrations of Bacteriostatic Antibiotics Induce relA-Dependent and relA-Independent Tolerance to β-Lactams
por: Kudrin, Pavel, et al.
Publicado: (2017)

Biochemical studies on Francisella tularensis RelA in (p)ppGpp biosynthesis
por: Wilkinson, Rachael C., et al.
Publicado: (2015)

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
por: Osborne, C K, et al.
Publicado: (2004)

Fulvestrant in advanced breast cancer: evidence to date and place in therapy
por: Boér, Katalin
Publicado: (2017)

Influence of the relA gene on ribosome frameshifting
por: Masucci, J., et al.
Publicado: (2002)

Identification of genes responsible for RelA-dependent proliferation arrest in human mammary epithelial cells conditionally expressing RelA
por: Kochupurakkal, Bose S., et al.
Publicado: (2015)

NF-κB/Rel Transcription Factors in Pancreatic Cancer: Focusing on RelA, c-Rel, and RelB
por: Kabacaoglu, Derya, et al.
Publicado: (2019)

Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer
por: Liu, Qi, et al.
Publicado: (2023)

Fulvestrant treatment of precocious puberty in girls with McCune-Albright syndrome
por: Sims, Emily K, et al.
Publicado: (2012)

Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer
por: Yi, Jun Ho, et al.
Publicado: (2014)

Tamoxifen and fulvestrant induced steatohepatitis with cirrhosis: A rare case report
por: Roy, Somnath, et al.
Publicado: (2019)

Endoxifen and fulvestrant regulate estrogen-receptor α and related DEADbox proteins
por: Asberger, Jasmin, et al.
Publicado: (2020)

A method to detect fulvestrant interference in estradiol in breast cancer patients
por: Brito, Margarida, et al.
Publicado: (2023)

A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis
por: Xu, Liang, et al.
Publicado: (2018)

Functional relevance of novel p300-mediated lysine 314 and 315 acetylation of RelA/p65
por: Buerki, Christine, et al.
Publicado: (2008)

ZBTB2 increases PDK4 expression by transcriptional repression of RelA/p65
por: Kim, Min-Young, et al.
Publicado: (2015)

The RelA hydrolase domain acts as a molecular switch for (p)ppGpp synthesis
por: Sinha, Anurag Kumar, et al.
Publicado: (2021)

relA Enhances the Adherence of Enteropathogenic Escherichia coli
por: Spira, Beny, et al.
Publicado: (2014)

relA Inactivation Converts Sulfonamides Into Bactericidal Compounds
por: Si, Lizhen, et al.
Publicado: (2021)

Forkhead Transcription Factor FOXP3 Upregulates CD25 Expression through Cooperation with RelA/NF-κB
por: Camperio, Cristina, et al.
Publicado: (2012)

The Exposure of Breast Cancer Cells to Fulvestrant and Tamoxifen Modulates Cell Migration Differently
por: Lymperatou, Dionysia, et al.
Publicado: (2013)

Effects of fulvestrant on biological activity and Wnt expression in rat GH3 cells☆
por: Bai, Jiwei, et al.
Publicado: (2012)

Fulvestrant-Mediated Inhibition of Estrogen Receptor Signaling Slows Lung Cancer Progression
por: Tang, Hexiao, et al.
Publicado: (2014)

The role of RelA (p65) threonine 505 phosphorylation in the regulation of cell growth, survival, and migration
por: Msaki, Aichi, et al.
Publicado: (2011)

Thr(435) phosphorylation regulates RelA (p65) NF-κB subunit transactivation
por: O'Shea, John M., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ljet4r0i8klqa6kno0ph6sjbtj